Nora Mohn

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Editorial: Novel insights into CAR T-cell associated neurotoxicity, volume II.

Editorial: Novel insights into CAR T-cell associated neurotoxicity, volume II.

Journal: Frontiers in neurology

Published: May 19, 2026

Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis.

Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis.

Journal: Transplantation and cellular therapy

Published: February 09, 2026

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

Journal: JAMA neurology

Published: January 20, 2026

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Journal: Brain : a journal of neurology

Published: December 30, 2025

Imaging of neurological adverse events associated with immunotherapies : Immune checkpoint inhibitors and CAR-T cells

Imaging of neurological adverse events associated with immunotherapies : Immune checkpoint inhibitors and CAR-T cells

Journal: Radiologie (Heidelberg, Germany)

Published: November 06, 2025

The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.

The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.

Journal: Frontiers in neurology

Published: October 16, 2025

Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis.

Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis.

Journal: Frontiers in neurology

Published: October 06, 2025

Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study.

Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study.

Journal: Oncology research

Published: October 01, 2025

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.

Journal: Oncoimmunology

Published: August 16, 2025

Does Interrater Variation Influence the Classification According to the Diagnostic Criteria for Multiple Sclerosis?

Does Interrater Variation Influence the Classification According to the Diagnostic Criteria for Multiple Sclerosis?

Journal: European journal of neurology

Published: June 09, 2025

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.

Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.

Journal: Neurological research and practice

Published: May 20, 2025

Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.

Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.

Journal: Journal of neurology

Published: March 29, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026